AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
14 Aprile 2021 - 10:05PM
Business Wire
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”)
announced today that they have entered into a strategic
multi-target discovery collaboration. Through each company’s
proprietary technologies, the multi-target collaboration leverages
hyper-scale datasets, machine learning, and advanced computation to
both identify high-value, genetically-validated drug targets and
discover novel therapeutic antibodies. Empirico will use its
Precision Insights Platform, a human genetics-focused discovery
platform, to select up to five therapeutic targets. AbCellera will
use its AI-powered antibody discovery technology to search and
analyze natural immune responses to identify antibodies with the
desired therapeutic properties against the selected targets.
Under the terms of the agreement, Empirico will have the rights
to develop and commercialize novel antibodies resulting from the
collaboration. AbCellera will receive research payments and is
eligible to receive downstream clinical and commercial milestone
payments and royalties on net sales of products from Empirico.
“One of the biggest challenges in drug development is the lack
of translation between preclinical models and human disease.
Empirico’s platform seeks to overcome this hurdle by uncovering
causal relationships between human genetic variation and clinical
outcomes to discover and validate targets,” said Carl Hansen,
Ph.D., CEO and President of AbCellera. “We are excited to partner
with Empirico and serve as its operating system for developing new
antibody-based therapies against genetically-validated
targets.”
“Using our Precision Insights Platform, Empirico has discovered
multiple genetically-validated targets for diseases with unmet
medical need, several of which are amenable to modulation with
therapeutic antibodies,” said Omri Gottesman, M.D., CEO and
President of Empirico. “For these and future programs, our
partnership with AbCellera empowers and enables us to rapidly
translate therapeutic insights from human genetics into potential
new medicines for patients in need.”
About Empirico Inc.
Empirico is a next-generation therapeutics company founded on
utilizing human genetics, data science and programmable biology to
power novel target discovery and development. Empirico’s Precision
Insights Platform, a proprietary human genetics-focused discovery
platform, leverages a world-leading dataset, hyperscale
infrastructure and algorithmic approaches that encode and enhance
human intuition to identify and prioritize therapeutic targets. All
potential therapeutic targets are subjected to rigorous in vitro
and in vivo experimental validation to elucidate the mechanism by
which genetic variation impacts disease risk and provide insights
about which therapeutic modality could be ‘programmed’ to mimic or
interfere with that mechanism. Empirico is advancing multiple
preclinical programs across a broad range of indications and
therapeutic modalities, both independently and in collaboration
with industry partners. Empirico is headquartered in San Diego,
Calif. with laboratories in Madison, Wis. To learn more about
Empirico, visit www.empiricotx.com.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements, including
statements regarding our ability to develop, commercialize and
achieve market acceptance of our current and planned products and
services, our research and development efforts, and other matters
regarding our business strategies, use of capital, results of
operations and financial position, and plans and objectives for
future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210414005756/en/
Inquiries: AbCellera Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236) 521-6774 Business Development: Kevin
Heyries, Ph.D.; bd@abcellera.com, +1(604) 559-9005 Investor
Relations: ir@abcellera.com, +1(778) 729-9116
Empirico Media: Jessica Yingling, Ph.D.; media@empiricotx.com,
+1(858) 344-8091 Business Development: Andy Spencer, Ph.D.;
bd@empiricotx.com
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024